Immunosuppressants

Psychosomatics

Volumn 45, Issue 4, 2004, Pages 354-360

  Fireman, Marian ^a   DiMartini, Andrea F ^b   Armstrong, Scott C ^a,c   Cozza, Kelly L ^d,e  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c Tuality Forest Grove Hospital   (United States)

^d WALTER REED ARMY MEDICAL CENTER   (United States)

^e UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIFUNGAL AGENT; ATORVASTATIN; AZATHIOPRINE; BASILIXIMAB; CLARITHROMYCIN; CYCLOSPORIN; DIGOXIN; DILTIAZEM; ERYTHROMYCIN; FLUCONAZOLE; FLUVOXAMINE; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEFAZODONE; OKT 3; PREDNISOLONE; PREDNISONE; RAPAMYCIN; RITONAVIR; SERTRALINE; SIMVASTATIN; TACROLIMUS; UNINDEXED DRUG; VERAPAMIL;

COMORBIDITY; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG INHIBITION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIAISON PSYCHIATRY; REVIEW; SIDE EFFECT; TRANSPLANTATION; TREATMENT INDICATION;

EID: 3042555335     PISSN: 00333182     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.psy.45.4.354     Document Type: Letter

References (46)

1. Olyaei AJ, deMattos AM, Bennett WM: Drug-drug interactions and most commonly used drugs in transplant recipients (in preparation, available from first author upon request)
2. Warrington JS, Shaw LM: Pharmacokinetic interactions of immunosuppressive agents after organ transplantation. Medscape CME January 29, 2004; http://www.medscape.com (accessed 2/9/ 2004)
3. Armstrong SC, Cozza KL, Pimentel EA: Med-psych drug-drug interactions update. Psychosomatics 2002; 43:424-427
4. Pimentel EA: Transplant surgery and rheumatology, in Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-glycoproteins, 2nd edition. Edited by Cozza KL, Armstrong SC, Oesterheld J. Arlington, Va, American Psychiatric Publishing, 2003, pp 383-396
5. Levy GL: Long-term immunosuppression and drug interactions. Liver Transplantation 2001; 11:S53-S59
6. Cozza KL, Armstrong SC, Oesterheld J: Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-glycoproteins, 2nd edition. Arlington,Va, American Psychiatric Publishing, 2003
7. Lo A, Burckart GP: P-glycoprotein and drug therapy in organ transplantation. J Clin Pharm 1999; 39:995-1005
8. DiMartini AF, Dew MA, Trzepacz PT: Organ transplantation, in Textbook of Psychosomatic Medicine. Edited by Levenson JL. Arlington, Va, American Psychiatric Publishing (in press)
9. Smith SL: Immunosuppressive therapies in organ transplantation. Medscape CME posted 6/25/2002; http://www.medscape.com (accessed 4/24/2004)
10. Varis T, Backman JT, Kivisto K, Neuvonen PJ: Diltiazem and mibefradil increase the plasma concentrations and greatly enhance the adrenal-suppressant effect of oral methyprednisolone. Clin Pharm Therapeutics 2000; 67:215-221
11. Wright DH, Lake KD, Bruhn PS, Emery RW: Nefazodone and cyclosporine drug-drug interaction. J Heart Lung Transplantation 1999; 18:913-915
12. Cohen E, Kramer M, Maoz C, Ben-Dayan D, Garty M: Cyclosporine drug-interaction-induced rhabdomyolysis. a report of two cases in lung transplant recipients. Clin Transplant 2000; 70:119-122
13. Vella JP, Sayegh MH: Interactions between cyclosporine and newer antidepressant medications. Am J Kidney Diseases 1998; 31:320-323
14. Lill J, Bauer LA, Horn JR, Hansten PD: Cyclosporine-drug interactions and the influence of patient age. Am J Health Syst Pharm 2000; 57:1579-1584
15. Page RL, Ruscin JM, Fish D, LaPointe M: Possible interaction between intravenous azithromycin and oral cyclosporine. Pharmacotherapy 2001; 21:1436-1443
16. Kane GC, Lipsky JJ: Drug-grapefruit juice interactions. Mayo Clinic Proceedings 2000; 75:933-942
17. Kusus M, Stapleton DD, Lertora JJL, Simon EE, Dreisbach AW: Rhabdomyolysis and acute renal failure in a cardiac transplant recipient due to multiple drug interactions. Am J Med Sci 2000; 320:394-397
18. Caforio ALP, Gambino A, Tona F, Feltrin G, Marchini F, Pompei E, Testolin L, Angelini A, Dalla Volta S, Casarotto D: Sulfinpyrazone reduces cyclosporine levels: a new drug interaction in heart transplant recipients. J Heart Lung Transplant 2000; 19:1205-1208
19. Ernst E: St John's wort supplements endanger the success of organ transplantation. Arch Surg 2002; 137:316-319
20. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G: Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355:548-549
21. Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR: St John's wort: a hidden risk for transplant patients. Prog Transplant 2001; 11:116-120
22. Christians U, Jacobsen W, Benet LZ, Lampen A: Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41:813-851
23. van Gelder T: Drug interactions with tacrolimus. Drug Safety 2002; 25:707-712
24. Moreno M, Latorre A, Manzanares C, Morales E, Herrero JC, Dominguez-Gil B, Carreno A, Cubas A, Delgado M, Andres A, Morales JM: Clinical management of tacrolimus drug interactions in renal transplant patients. Transplantation Proceedings 1999; 31:2252-2253
25. Cervelli M, Russ GR: Itraconazole-tacrolimus drug interaction. Ther Drug Monit 2003; 25:483-484
26. Butani L, Berg G, Makker SP: Effect of felodipine on tacrolimus pharmacokinetics in a renal transplant patient. Transplantation 2002; 73:159
27. Taber DJ, Dupuis RE, Hollar KD, Strzalka AL, Johnson MW: Drug-drug interaction between chloramphenicol and tacrolimus in a liver transplant recipient. Transplantation Proceedings 2000; 32:660-662
28. Vasquez EM, Pollak R, Benedetti E: Clotrimazole increases tacrolimus blood levels: a drug interaction in kidney transplant patients. Clin Transplant 2001; 15:95-99
29. Campo JV, Smith C, Perel JM: Tacrolimus toxic reaction associated with use of nefazodone: paroxetine as an alternative agent. Arch Gen Psych 1998; 55:1050-1053
30. Omar G, Shah A, Thomson AW, Whiting PH, Burke MD: FK 506 inhibition of cyclosporine metabolism by human liver microsomes. Transplantation Proceedings 1991; 23:934-935
31. Kotanko P, Kirisits W, Skrabal F: Rhabdomyolysis and acute renal graft impairment in a patient treated with simvastatin, tacrolimus and fusidic acid. Nephron 2002; 90:234-235
32. Gomet JM, Lokiec F, Duclos-Vallee JC, Azoulay D, Goldwasser F: Severe CPT-11-induced diarrhea in the presence of FK-506 following liver transplantation for hepatocellular carcinoma. Anticancer Research 2001; 21:4203-4206
33. Barshes NR, Goodpastor SE, Goss JA: Sirolimus-atorvastatin drug interaction in the pancreatic islet transplant recipient. Transplantation 2003; 76:1649-1650
34. Cervelli MJ: Fluconazole-sirolimus drug interaction. Transplantation 2002; 74:1477-1478
35. Mahalati K, Kahan BD: Clinical pharmacokinetics of sirolimus. Clin Pharmacokinet 2001; 40:573-585
36. Smak Gregoor PJH, De Sevaux RGL, Hene RJ, Hesse CJ, Hilbrands LB, Vos P, van Gelder T, Hoitsma AJ, Weimar W: Effect of cyclosporine on mycophenolic acid trough levels in kidney transplant recipients. Transplantation 1999; 68:1603-1606
37. van Gelder T, Smak Gregoor PJH, Weimar W: Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients (letter). Ther Drug Monit 2000; 22:639
38. Hubner GI, Eismann R, Sziegoleit W: Drug interaction between mycophenolate mofetil and tacrolimus detectable within therapeutic mycophenolic acid monitoring in renal transplant patients. Ther Drug Monit 1999; 21:536-539
39. Schwartz JB: Pharmacogenetics: has it reached the clinic? J Gender Specific Medicine 2002; 5:13-18
40. Walker J, Mendelson H, McClure A, Smith MD: Warfarin and azathioprine: clinically significant drug interaction. J Rheumatology 2002; 29:398-399
41. Cummins D, Sekar M, Halil O, Banner N: Myelosuppression associated with azathioprine-allopurinol interaction after heart and lung transplantation. Transplantation 1996; 61:1661-1662
42. Pescovitz MD: Reducing acute rejection with monoclonal antibodies. Medscape CME December 17, 2001; http://www.medscape.com (accessed 4/24/2004)
43. Olyaei AJ, Thi K, deMattos AM, Bennett WM: Use of basiliximab and daclizumab in kidney transplantation. Prog Transplant 2001; 11:33-39
44. Vasquez EM, Pollak R: OKT3 therapy increases cyclosporine blood levels. Clinical Transplantation 1997; 11:38-41
45. Sifontis NM, Benedetti E, Vasquez EM: Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipients. Transplantation Proceedings 2002; 34:1730-1732
46. Strehlau J, Pape L, Offner G, Nashan B, Ehrlich JHH: Interleukin-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipients. Lancet 2000; 356:1327-1328